Made for the world
We are committed to changing the course of the pandemic with a vaccine made for the world. No one is safe until all of us are safe.
For more information, please visit our newly launched website.
Our response to COVID-19
AstraZeneca is responding to the COVID-19 (novel coronavirus) outbreak, consistent with our values to follow the science, put patients first and do the right thing. Our priorities are to ensure the continued supply of our medicines to patients, and to safeguard the health and wellbeing of all our employees and communities. On this page we provide an overview of what we are doing to support the COVID-19 response.
The European Medicines Agency reaffirms that the overall benefits of AstraZeneca’s COVID-19 vaccine continues to outweigh risks
US Phase III primary analysis confirms safety and efficacy of AstraZeneca’s COVID-19 vaccine
Peer-reviewed primary analysis of Phase III trials with AstraZeneca’s Covid-19 vaccine published
AZD1222 Oxford Phase III trials interim analysis results published in The Lancet
AstraZeneca concludes agreement for supply of AZD1222 COVID-19 vaccine to Switzerland
AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s vaccine at no profit